Unique ID issued by UMIN | UMIN000053516 |
---|---|
Receipt number | R000061077 |
Scientific Title | Long-term follow-up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patient |
Date of disclosure of the study information | 2024/02/01 |
Last modified on | 2024/02/01 17:54:41 |
Long-term follow-up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patient
Long-term follow-up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patient
Long-term follow-up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patient
Long-term follow-up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patient
Japan |
onychomycosis
Dermatology |
Others
NO
In the present study, we continued the follow-up and investigated the efficacy of re-administration of fosravuconazole in patients with recurrent onychomycosis.
Safety,Efficacy
1)Patient characteristics: Sex, age, and presence or absence of diabetes/renal failure (on dialysis treatment)/use of immunosuppressive drugs.
Others,meta-analysis etc
65 | years-old | <= |
Not applicable |
Male and Female
Among patients aged 65 years or older who visited our dermatology outpatient clinic from November 2018 to March 2021, those who were diagnosed with onychomycosis by KOH-based direct microscopy and requested oral treatment were included in the study. Fosravuconazole was administered orally (100 mg/day) for an initial 12 weeks. One hundred and twenty-five patients judged to have responded to the treatment at 48 weeks after completion of the treatment were followed up for subsequent 144 weeks. Patients who experienced a recurrence at less than 24 weeks during the follow-up period were assigned to the short-term recurrence group, and those who experienced a recurrence at 24 weeks or later were assigned to the long-term recurrence group. Fosravuconazole was re-administered and the efficacy was evaluated in each group.
Patients with hepatic impairment (AST or ALT: 2.5 times the upper reference limit or 100 U/L) and patients having been treated with warfarin were excluded from this study.
200
1st name | AYAKA |
Middle name | |
Last name | OKUBO |
Muroran City General Hospital
Department of Dermatology
051-8512
3-8-1 Yamate-cho, Muroran-shi, Hokkaido 051-8512, Japan.
09050762413
m59_anomura@yahoo.co.jp
1st name | AYAKA |
Middle name | |
Last name | OKUBO |
Muroran City General Hospital
Department of Dermatology
0510012
3-8-1 Yamate-cho, Muroran-shi, Hokkaido 051-8512, Japan.
09050762413
murohosp191@kujiran.jp
Muroran City General Hospital
Muroran City General Hospital
Local Government
Muroran City General Hospital
3-8-1 Yamate-cho, Muroran-shi, Hokkaido 051-8512, Japan.
0143253111
murohosp191@kujiran.jp
NO
2024 | Year | 02 | Month | 01 | Day |
Unpublished
200
The results suggest that the re-administration of fosravuconazole is safe and as effective as the first administration for elderly patients with recurrent onychomycosis.
2024 | Year | 02 | Month | 01 | Day |
2024 | Year | 03 | Month | 01 | Day |
Completed
2018 | Year | 09 | Month | 01 | Day |
2018 | Year | 09 | Month | 01 | Day |
2018 | Year | 09 | Month | 01 | Day |
2023 | Year | 12 | Month | 31 | Day |
Other related information
2024 | Year | 02 | Month | 01 | Day |
2024 | Year | 02 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061077
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |